Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review
Yinfang Gu, Lilan Yi, Xiaofang Zou, Longhua Guo, Guowu Wu, Jingjing Zhao · 2024
Read Refractory hypokalemia and metabolic acidosis induced by undifferentiated connective tissue disease secondary to immune checkpoint inhibitors: a case report and literature review by Yinfang Gu, Lilan Yi, Xiaofang Zou, Longhua Guo, Guowu Wu, Jingjing Zhao (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11628383.txt.
Description
Six doctors in China report a case where a cancer drug caused stubborn low potassium through an autoimmune side effect, in a paper published in 2024. The patient, a forty-year-old with melanoma, had taken the immune drug camrelizumab for six months. He grew tired and his blood potassium fell, and standard potassium doses failed to fix it. Tests pointed to a kidney acid problem driven by an unnamed connective tissue disease.
With potassium citrate and an immune-calming drug, his blood values and energy returned to normal. When the cancer drug restarted, the problem came back in full, and it cleared only after the drug stopped for good. No relapse followed once the drug was dropped. The authors urge doctors to watch potassium during such therapy and to think of kidney and autoimmune causes when low levels resist treatment.
Catalog record
| CREATOR | Yinfang Gu, Lilan Yi, Xiaofang Zou, Longhua Guo, Guowu Wu, Jingjing Zhao |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |